Á¦  ¸ñ :   ´ç´¢º´ ȯÀÚ, ¼Õ³¡ äÇ÷ ´ë½Å '¿¬¼ÓÇ÷´çÃøÁ¤'Çß´õ´Ï... "¾à ¾È ´Ã·Áµµ Ç÷´ç ¶Ò"

¿¬¼ÓÇ÷´çÃøÁ¤±â¸¦?»ç¿ëÇÑ?Á¦2Çü?´ç´¢º´?ȯÀÚ°¡?¼Õ°¡¶ô?äÇ÷À»?ÅëÇØ?Ç÷´çÀ»?Àç´Â?±âÁ¸?¹æ½ÄÀÇ?ȯÀÚº¸´Ù?Ç÷´ç?Á¶ÀýÀÌ?´õ Àß?µÆ´Ù´Â?¿¬±¸?°á°ú°¡?³ª¿Ô´Ù.?¿µ±¹?³ëÆÃ¾ö´ë?ÀÇ´ë?¿¥¸¶?Àª¸ø(Emma?G?Wilmot)?ºÎ±³¼ö¿Í?Àӯ䏮¾óÄ®¸®Áö·±´ø?¶ó¶õŸ?¸±¶ó¶óÆ®³ª(Lalantha?Leelarathna)?ºÎ±³¼ö?°øµ¿?¿¬±¸ÆÀÀº?¿µ±¹?24°³?1?2Â÷?ÀÇ·á±â°ü¿¡¼­?Á¦2Çü?´ç´¢?ȯÀÚ?303¸íÀ»?32ÁÖ°£?ÃßÀûÇØ?À̰°ÀÌ?¹àÇô³Â´Ù.?À̹ø?¿¬±¸´Â?ÃÖ½Å?´ç´¢¾àÀ»?¾²´Âµ¥µµ?Ç÷´ç?Á¶ÀýÀÌ?ÀßµÇÁö?¾Ê´Â?ȯÀڵ鿡°Ô?¿¬¼ÓÇ÷´çÃøÁ¤±â°¡?½ÇÁúÀûÀÎ?µµ¿òÀÌ?µÉ?¼ö?ÀÖÀ½À»?º¸¿©ÁØ´Ù.

¿¬±¸ÆÀÀº 2023³â 7¿ùºÎÅÍ 2025³â 1¿ù±îÁö Àν¶¸°°ú ÇÔ²² SGLT2 ¾ïÁ¦Á¦ ¶Ç´Â GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ µî ÃֽŠ´ç´¢º´ ¾àÀ» ¾²°í ÀÖ´Â 18¼¼ ÀÌ»ó ȯÀÚ Áß ´çÈ­Ç÷»ö¼Ò°¡ 7.5~11.0%ÀÎ »ç¶÷µéÀ» ¸ðÁýÇß´Ù. ´çÈ­Ç÷»ö¼Ò(HbA1c)´Â Áö³­ 2~3°³¿ù µ¿¾ÈÀÇ Æò±Õ Ç÷´ç »óŸ¦ º¸¿©ÁÖ´Â ÁöÇ¥·Î, ¼öÄ¡°¡ ³ôÀ»¼ö·Ï ÇÕº´Áõ À§ÇèÀÌ Ä¿Áø´Ù. Âü°¡ÀÚ 303¸íÀ» 2´ë 1 ºñÀ²·Î ³ª´² 198¸í¿¡°Ô´Â ¿¬¼ÓÇ÷´çÃøÁ¤±â¸¦, 105¸í¿¡°Ô´Â ±âÁ¸ÀÇ ¼Õ°¡¶ô äÇ÷ ¹æ½ÄÀ» ±×´ë·Î »ç¿ëÇÏ°Ô ÇÑ µÚ 32ÁÖ°£ ºñ±³Çß´Ù. Âü°¡ÀÚ Æò±Õ ³ªÀÌ´Â 60.7¼¼, Æò±Õ ´ç´¢ À¯º´ ±â°£Àº 16.7³âÀ̾ú´Ù.

¿¬±¸´Â?µÎ?´Ü°è·Î?³ª´²?ÁøÇàµÆ´Ù.?1~16ÁÖÂ÷´Â?ȯÀÚ?½º½º·Î?Ç÷´ç?ÀڷḦ?º¸¸ç?°ü¸®ÇÏ´Â?Àڱ⠰ü¸®?±â°£,?17~32ÁÖÂ÷´Â?ÀÇ·áÁøÀÌ?¾à¹°À»?Ãß°¡Çϸç?Àû±Ø?°³ÀÔÇÏ´Â?±â°£À̾ú´Ù.?ºÐ¼®?°á°ú,?16ÁÖ?ÈÄ?¿¬¼ÓÇ÷´çÃøÁ¤±â?±×·ìÀÇ?´çÈ­Ç÷»ö¼Ò´Â?8.8%¿¡¼­?8.0%·Î?¶³¾îÁø?¹Ý¸é,?¼Õ°¡¶ô?äÇ÷?±×·ìÀº?8.8%¿¡¼­?8.7%·Î?°ÅÀÇ?º¯È­°¡?¾ø¾ú´Ù.?µÎ?±×·ì?°£?Â÷ÀÌ´Â?0.6% p¿´´Ù.?32ÁÖ?ÈÄ¿¡µµ?Â÷ÀÌ´Â?À¯ÁöµÅ?¿¬¼ÓÇ÷´çÃøÁ¤±â?±×·ìÀº?7.8%±îÁö?Ãß°¡·Î?¶³¾îÁ³°í,?¼Õ°¡¶ô?äÇ÷?±×·ìÀº?8.3%¿¡?¸Ó¹°·¶´Ù.?Á¤»ó?Ç÷´ç?¹üÀ§¿¡?¸Ó¹«´Â?½Ã°£?ºñÀ²µµ?32ÁÖ?½ÃÁ¡¿¡?60.2%´ë?50.1%·Î?¾à?10%?p?Â÷À̰¡?³µ´Ù.

Èï¹Ì·Î¿î?Á¡Àº?Àڱ⠰ü¸®?±â°£¿¡?µÎ?±×·ìÀÇ?Àν¶¸°?»ç¿ë·®¿¡?Â÷À̰¡?¾ø¾ú´Ù´Â?»ç½ÇÀÌ´Ù.?Áï?¾àÀ»?´õ?¾´?°á°ú°¡?¾Æ´Ï¶ó,?ȯÀÚµéÀÌ?½Ç½Ã°£À¸·Î?º¯ÇÏ´Â?Ç÷´ç?¼öÄ¡¸¦?º¸¸é¼­?½Ä»ç¿Í?Ȱµ¿À»?½º½º·Î?Á¶ÀýÇÑ?°á°ú·Î?ºÐ¼®µÈ´Ù.?½ÇÁ¦·Î?¿¬¼ÓÇ÷´çÃøÁ¤±â?±×·ìÀº?16ÁÖ?½ÃÁ¡¿¡?ÀÏ»ó?½Åü Ȱµ¿·®ÀÌ?´õ?´Ã¾ú°í,?½Ä½À°ü?Á¡¼öµµ?´õ?ÁÁ¾ÆÁø?°ÍÀ¸·Î?³ªÅ¸³µ´Ù.?¾ÈÀü¼º?¸é¿¡¼­µµ?ÀǽÄÀ»?ÀÒÀ»?¼ö?ÀÖ´Â?½ÉÇÑ?ÀúÇ÷´çÀº?¼Õ°¡¶ô?äÇ÷?±×·ìÀÇ?ÇÑ?¸í¿¡°Ô¼­¸¸?µÎ?Â÷·Ê?¹ß»ýÇß°í,?¿¬¼ÓÇ÷´çÃøÁ¤±â?±×·ì¿¡¼­´Â?´Ü?ÇÑ?°Çµµ?¾ø¾ú´Ù.

¿¬±¸ÀÇ?°øµ¿?Ã¥ÀÓÀúÀÚÀÎ?¿¥¸¶?Àª¸ø(Emma?G?Wilmot)?¿µ±¹?³ëÆÃ¾ö´ë?ÀÇ´ë?ºÎ±³¼ö´Â?"À̹ø?¿¬±¸´Â?±âÁ¸?ÃÖ½Å?¾à¹°Ä¡·á¸¦?¹Þ´Âµ¥µµ?Ç÷´ç?¸ñÇ¥¿¡?µµ´ÞÇÏÁö?¸øÇÏ´Â?ȯÀڵ鿡°Ô?¿¬¼ÓÇ÷´çÃøÁ¤±â°¡?½ÇÁúÀûÀÎ?µµ¿òÀÌ?µÉ?¼ö?ÀÖÀ½À»?ÀÔÁõÇÑ?°á°ú"¶ó¸ç?"ȯÀÚ?½º½º·ÎÀÇ?Àڱ⠰ü¸®?´Ü°è¿¡¼­?À̹Ì?È¿°ú°¡?³ªÅ¸³µ°í,?ÀÌÈÄ?ÀÇ·áÁøÀÇ?¾à¹°?Á¶Á¤ÀÌ?´õÇØÁ³À»?¶§?±×?È¿°ú°¡?±×´ë·Î?À¯ÁöµÆ´Ù´Â?Á¡ÀÌ?ÇÙ½É"À̶ó°í?¸»Çß´Ù.

À̹ø ¿¬±¸ °á°ú(Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: Á¦2Çü ´ç´¢ ȯÀÚ¿¡¼­ ¿¬¼ÓÇ÷´çÃøÁ¤°ú ÀÚ°¡Ç÷´çÃøÁ¤ ºñ±³)´Â Áö³­ 4¿ù 23ÀÏ ±¹Á¦ ÇмúÁö '¶õ¼Â ´ç´¢º´&³»ºÐºñÇÐ(The Lancet Diabetes & Endocrinology)'¿¡ ¿Â¶óÀÎ °ÔÀçµÆ´Ù.



´ÙÀ½±Û : "¼¤Çª ¼Ó È­ÇÐ ¼ººÐÀÌ Å»¸ð À¯¹ß "... ³ëǪ ¿­Ç³ÀÇ Áø½ÇÀº [ÆÑÆ®ÁøÂû´ë]
ÀÌÀü±Û : ÇϹöµå´ëµµ ÁÖ¸ñÇÑ 'ÄÚ ½ºÇÁ·¹ÀÌ'... È£Èí±â °¨¿° ¿¹¹æ Æ®·»µå ¹Ù²ï´Ù